Meeting
2015 ASCO Annual Meeting
Phase II study with conventional radiotherapy (RT) + cetuximab in patients with advanced larynx cancer who responded to induction chemotherapy (IC): An organ preservation TTCC study.
Authors
Ricard Mesia Sr.
Institut Catala d'Oncologia, Barcelona, Spain
Ricard Mesia Sr., Jose Angel Garcia Saenz , Alicia Lozano , Miguel Pastor Sr., Juan José Grau , Javier Martinez Trufero , Julio Jose Lambea- Sorrosal , Joaquina Martinez Galan , Jose Ramón Mel , Belen Gonzalez , Silvia Vazquez , Manel Manos Pujol , Miren Taberna , Beatriz Cirauqui , Elvira del Barco , Esther Casado , Jordi Rubió , Angeles Rodriguez Jaraiz , Juan J. Cruz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
2008-000332-40
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6037)
DOI
10.1200/jco.2015.33.15_suppl.6037
Abstract #
6037
Poster Bd #
360
Abstract Disclosures
Similar Posters
First Author: Andreas Dietz
Poster
2016 ASCO Annual Meeting
TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.
First Author: Pol M. Specenier
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli